Kobayashi Pharmaceutical Co., Ltd. acquired Alva-Amco Pharmacal Companies, Inc. from Trusts all owned by the founder's family for approximately $110 million.
September 29, 2020
Share
Kobayashi Pharmaceutical Co., Ltd. (TSE:4967) signed an contract to acquire Alva-Amco Pharmacal Companies, Inc. from Trusts all owned by the founder's family for approximately $110 million on September 30, 2020. Alva-Amco Pharmacal Companies reported sales of $32.5 million for the year ended October 31, 2019. The boards of directors of both Kobayashi Pharmaceutical and Alva have each approved the acquisition, but the execution of the acquisition may require the fulfillment of conditions under the US Antimonopoly Act. The transaction is expected to complete by the end of October 2020. Lincoln International LLC acted as financial advisor to Alva-Amco Pharmacal Companies, Inc.
Kobayashi Pharmaceutical Co., Ltd. (TSE:4967) completed the acquisition of Alva-Amco Pharmacal Companies, Inc. from Trusts all owned by the founder's family in the end of last month.
KOBAYASHI PHARMACEUTICAL CO., LTD. a drug manufacturer. The Company operates in three segments. The Domestic Household Products Manufacturing and Sales segment and Overseas Household Products Manufacturing and Sales segment offer health care, daily necessities, skin care and other products. The Mail Order segment involves in the mail order of dietary supplements, skin care products and others.
Kobayashi Pharmaceutical Co., Ltd. acquired Alva-Amco Pharmacal Companies, Inc. from Trusts all owned by the founder's family for approximately $110 million.
KOBAYASHI PHARMACEUTICAL CO., LTD. 
